HGSC mortality: BRCA1 or BRCA2
It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes HGSC mortality: BRCA1 or BRCA2 compared with no RRSO (very low certainty).
1 finding from 1 review
Severe adverse events
4 findings from 1 review
no estimate extracted
0 studies · 0 participants
GRADE not reported
no estimate extracted
0 studies · 0 participants
GRADE not reported
no estimate extracted
0 studies · 0 participants
GRADE not reported
Show 1 more finding
Overall survival
2 findings from 1 review
HGSC mortality
2 findings from 1 review
Breast cancer mortality: ≤ 50 years
It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: ≤ 50 years compared with no RRSO (very low certainty).
2 findings from 1 review
Breast cancer mortality: > 50 years
It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: > 50 years compared with no RRSO (very low certainty).
2 findings from 1 review
Breast cancer mortality: BRCA1 or BRCA
It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA1 or BRCA compared with no RRSO (very low certainty).
1 finding from 1 review
Quality of life (ovarian cancer risk perception): BRCA1 or BRCA2
1 finding from 1 review
Quality of life (breast cancer risk perception): BRCA1 or BRCA2
1 finding from 1 review
Overall survival: BRCA1 only
It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA1 only compared with no RRSO according to BRCA mutation status (very low certainty).
1 finding from 1 review
Overall survival: BRCA2 only
It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA2 only compared with no RRSO according to BRCA mutation status (very low certainty).
1 finding from 1 review
Survival · people with ALS
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · people with ALS
1 finding from 1 review
Quality of Life: SF‐36 (physical component) · people with ALS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SAQLI) · people with ALS
1 finding from 1 review
Adverse events (not reported) · people with ALS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline in MVIC Expressed as arm megascore1 · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of % predicted FVC · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline (per month) of functional rating scale (over a period of 9 months) Measured by ALSFRS‐R · people with ALS/MND
1 finding from 1 review